RxDoctor Payments Data

Jennifer Nelson, APRN

Adult Health · Shelton, CTNPI 1164409587

Payments from drug & device makers

$3,139in general payments, 2019–2025

Across 175 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$844
  • Abbott$573
  • Pfizer$381
  • Impulse Dynamics (USA) Inc.$200
  • Merck$191
  • Novartis$189
  • plus $761 from 11 others

What the payments were for

  • Food & beverage$3,139100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,139 in reported general payments places this provider in the 80th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$70,686
Medicare patients
301
Services billed
1,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$268,676
EntrestoSacubitril/Valsartan28$54,865
XareltoRivaroxaban30$44,750
MultaqDronedarone Hcl20$32,628
JardianceEmpagliflozin14$20,516
VerquvoVericiguat12$8,128
Dofetilide27$6,994
Propafenone Hcl ErPropafenone Hcl25$4,897
Metoprolol Succinate202$2,646
Flecainide Acetate55$2,597
Diltiazem 24hr Er (Cd)Diltiazem Hcl92$2,184
Nebivolol Hcl28$1,981
Mexiletine Hcl14$1,708
Amiodarone Hcl56$1,626
Valsartan46$886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$381$268,676177 claims
NovartisEntresto$189$54,86528 claims
Johnson & JohnsonXarelto$146$44,75030 claims
Sanofi-aventis U.S. LLCMultaq$139$32,62820 claims
MerckVerquvo$191$8,12812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 418 adult health providers in Connecticut.

Other adult health in Shelton

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →